UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 27, 2017

CELSION CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware	**001-15911**	**52-1256615**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

997 Lenox Drive, Suite 100, Lawrenceville, New Jersey 08648
(Address of Principal Executive Offices) (Zip Code)

(609) 896-9100
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On January 27, 2017, Celsion Corporation. (the Company) made available corporate presentation materials on the Company's website at www.celsion.com. A copy of the Company's presentation materials is attached hereto as Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including the Exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The Company undertakes no duty or obligation to update or revise information included in this Report or any of the Exhibits. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Cautionary Statements

This Current Report on Form 8-K and the presentations include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended , including information about the Company's plans and expectations regarding its clinical studies and related FDA and regulatory matters.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company's business are disclosed in the "Risk Factors" contained in the Company's 2015 Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Corporate Presentation materials

SIGNATURES

Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CELSION CORPORATION

Dated: January 27, 2017

By: */s/ Jeffrey W. Church*
Jeffrey W. Church
Senior Vice President and
Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Corporate Presentation materials


Celsion
Corporate Presentation
January 2017
Celsion

Safe Harbor Statement

This presentation and any statements made for and during any presentation or meeting contain forward-looking statements related to Celsion Corporation ("Celsion") under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

These statements may be identified by the use of forward-looking words such as "anticipate," "planned," "believe," "forecast," "estimated," "expected," and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. Such factors include, among other things, unforeseen changes in the course of research and development activities and in clinical trials; possible changes in cost, timing and progress of development, preclinical studies, clinical trials and regulatory submissions; Celsion's ability to obtain and maintain regulatory approval of any of its product candidates; possible changes in capital structure, financial condition, future working capital needs and other financial items; changes in approaches to medical treatment; introduction of new products by others; success or failure of our current or future collaboration arrangements, risks and uncertainties associated with possible acquisitions of other technologies, assets or businesses; the ability to obtain additional funds for operations; the ability to obtain and maintain intellectual property protection for technologies and product candidates and the ability to operate the business without infringing the intellectual property rights of others; the reliance on third parties to conduct preclinical studies or clinical trials; the rate and degree of market acceptance of any approved product candidates; possible actions by customers, suppliers, strategic partners, potential strategic partners, competitors and regulatory authorities; compliance with listing standards of The NASDAQ Capital Market; and those risks listed under "Risk Factors" as set forth in Celsion's most recent periodic reports filed with the Securities and Exchange Commission, including Celsion's Form 10-K for the year ended December 31, 2015.

While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Celsion does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances except as required by law.

Celsion

Oncology Company

Capital Efficient Drug Development

Nanoparticle-Based Technology Platforms Driving Growth

Targeted Chemotherapy

- Phase III Study in Primary Liver Cancer (The OPTIMA Study)
- Phase II Study in RCW Breast Cancer (The Euro-DIGNITY Study)

Gene Mediated Immuno-Oncology

- Phase I Neoadjuvant Therapy in 1st Line Ovarian Cancer (The OVATION Study)
- Phase I/II Combination Therapy with Avastin 2nd line Ovarian Cancer

Celsion

Our Two Clinical Stage Platforms

LTSL

Lysolipid Thermally
Sensitive Liposomes
Known Chemotherapeutics

ThermoDox®

Targeted Doxorubicin Delivery

- Phase III Study Enrolling in HCC
- Phase II Study in RCW Breast Cancer

TheraPlas™

Synthetic Non-viral Vector
DNA-based Plasmids
Therapeutic Proteins

GEN-1™

Localized IL-12 Immunotherapy

- Neoadjuvant Study in 1st Line Ovarian
- Combination Study with Avastin and Doxil in 2nd Line Ovarian Cancer

Celsion

Pipeline of Targeted Therapeutics

	INDICATION	PRODUCT CANDIDATE	PRE-CLINICAL	PHASE 1-2	PHASE 3
Clinical	Primary Liver	ThermoDox/OPTIMA Study			Phase III enrolling
	RCW Breast	ThermoDox /Euro-DIGNITY		Phase II initiating	
	Ovarian	GEN-1/OVATION Study		Phase I enrolling	
Pre-Clinical	MI Bladder Cancer	ThermoDox	Efficacy/Safety/Toxicology Complete		
	Glioblastoma	GEN-1	Efficacy/Safety/Toxicology		
	Lung	TheraSilence	Efficacy/Toxicology		

Celsion


Chemotherapy
ThermoDox®
Celsion
6

Hepatocellular Carcinoma

Large and Deadly Global Cancer

- **5th most prevalent**
  - 800,000 global incidence growing 5% annually
  - By 2020, expected to be the #1 cancer
  - China has 50% of new cases; 75% in Asia
- **4th highest mortality**
  - 5-year survival rate less than 10%
  - Median survival from time of diagnosis is less than 3 years[1]
  - Curative surgery is possible in less than 20% of patients
- **Local therapies include:**
  - RFA, TACE and radiation
  - RFA is the dominant treatment with local recurrence rates >50% for lesions >3 cm
  - ThermoDox + RFA addresses limitations of current standard of care by **"Expanding the Treatment Zone"**

Market Opportunity >200K Patients

[1] *Journal of Hepatology 2012 vol. 56 | 908-943*

Celsion

ThermoDox + RF Liver Ablation

Expanding the Treatment Zone Addresses RFA Limitations

- ThermoDox infused IV ~15 minutes prior to sRFA
- RFA ablates tumor and creates a "Thermal Zone" in margin surrounding the tumor
- Doxorubicin is released in the "Thermal Zone" expanding treatment area and killing the metastases outside the ablation zone



Celsion

RFA Dwell Time Matters!

Learnings from the 700 patient HEAT Study

- Pre-specified analysis of HEAT Study data showed that patients with smaller lesions (3-5 cm) appeared to do better with ThermoDox
- When standardized for dwell time and lesion number, ThermoDox patients demonstrated difference in Overall Survival
- The hypothesis that dwell time increases local doxorubicin concentration was demonstrated in a computational model
- The hypothesis was further tested and demonstrated in an in-vivo porcine model:



More RFA time = More local Dox deposition



15 Min Dwell Time



- Multivariate analysis points to RFA dwell time with ThermoDox as the factor correlating to significant improvement in survival

Celsion

ThermoDox: HCC

Sub-Group Analysis of HEAT Study Data

Greater than Two Years Overall Survival Benefit

285 Patients with Standardized RFA>45 minutes (sRFA)



Overall Survival as of 7/15/2016	HR=0.65 (95% CI 0.43 - 0.93)	*P* Value = 0.02

Celsion

RFA Dwell Time Matters!

Independent Confirmation from NIH Analysis of HEAT Study Data

Evaluated RFA burn time per tumor volume (min/ml) for correlation with clinical outcomes

Results:

Increase in burn time per tumor volume improves OS in ThermoDox + RFA patients compared to RFA only patients

For RFA + ThermoDox patients:

One unit increase in RFA duration per tumor volume improved OS by 20% (p=0.017, HR=0.836, n=227)

- More dramatic differences in subgroup of patients with RFA burn times per tumor volume > 2.5 minutes/ml
- Cox multiple covariate analysis showed OS to be significant (p=0.038, HR=0.85) - Increase in the burn time per tumor volume improves survival in the RFA + ThermoDox subjects compared to RFA only patients

NIH

For RFA-only patients:

Burn time per tumor volume did not have a significant effect (p=0.57; HR=0.99; n=210)

Celsion

NIH Confirms HEAT Study Sub-Group

KM of subjects with burn time > 2.5 min/ml (~45mins/3cm tumors)



Celsion

ThermoDox + RFA vs TACE

Intermediate HCC

	Study	Lesion size	N	Median OS (mos.)	Year 1 (%)	Year 2 (%)	Year 3 (%)
	HEAT Study ITT Population	Overall: 2.7 - 7.5 cm Mean: 4.2 cm Median: 4 cm	701	53 mos.	85%	76%	64%
HEAT Study Subgroup	**ThermoDox + RFA ≥ 45 min.**	**Overall: 2.7 - 6.9 cm Mean: 4.3 cm Median: 4.2 cm**	**138**	**80+ mos.**	**94%**	**85%**	**77%**
HEAT Study Subgroup	RFA alone time ≥ 45 min.	Overall: 3 - 6.9 cm Mean: 4.2 cm Median: 3.9 cm	147	57 mos.	88%	79%	69%
	Ikeda et al (TACE) 2013	Median: 3.9; range 1-11	99	37 mos.	90%	75%	NR
		> 3.0	64	NR	NR	66%	NR
	Burrel (DEB TACE) 2012	BCLC A	41	54 mos.	90%	NR	68%
		BCLC B	63	48 mos.	88%	NR	64%

Celsion

DEB TACE – Doxorubicin Eluding Beads

Review Article

The Clinical Management of Hepatocellular Carcinoma in the United States, Europe, and Asia

A Comprehensive and Evidence-Based Comparison and Review

Zhi Ven Fong, MD; and Kenneth K. Tanabe, MD

Hepatocellular carcinoma (HCC), the most common primary malignancy of the liver, represents 1 of the leading causes of cancer deaths in the world with an estimated 21,670 deaths in the United States in 2013. In contrast to other malignancies, there is an array of treatment options for HCC involving several specialties in the multidisciplinary care of the patient. Consequently, vast heterogeneity in management tendencies has been observed. The objective of this report was to review and compare guidelines on the management of HCC from the United States (National Comprehensive Cancer Network), Europe (European Association for the Study of the

Cancer September 15, 2014

TABLE 5. Survival Outcomes 3 Years After Surgical Resection and Radiofrequency Ablation of Hepatocellular Carcinoma Based Dichotomized Based on Tumor Size

	3-Year OS Rate, %			3-Year DFS Rate, %		
Tumor Size, cm	Resection	RFA	*P*	Resection	RFA	*P*
≤3	79	50	NS	67	34	NS
>3	59	24	.007	43	12	.003

Abbreviations: DFS, disease-free survival; NS, nonsignificant; OS, overall survival; RFA, radiofrequency ablation.

HEAT Study showed 3-Year OS Rate of 77% (July 2015)

Celsion

Phase III OPTIMA Study Design

General Eligibility
- Non-resectable HCC
- Single lesions
- Lesion > 3 cm but not > 7 cm
- Treatment naïve
- Child-Pugh A

Stratification
- Lesion size: 3-5 cm / 5-7 cm
- RFA Technique (Percutaneous, Laparoscopy, or Surgical)



Primary Endpoint	Overall Survival (OS)
Secondary Endpoints	Progression Free Survival; Safety
Interim Efficacy Analysis	118 OS Events / HR < 0.61 158 OS Events / HR < 0.70
Final Efficacy	197 OS Events / HR < 0.75

First Patient Enrolled
Q3 – 2014

~ 75 Clinical Sites in
14 Countries

* sRFA45 Standardized Radiofrequency Ablation > 45 minutes

Celsion

ThermoDox: RCW Breast Cancer

Difficult to Treat with Severe Complications

- Breast cancer recurring in the chest wall affects ~35,000 post-mastectomy patients in the US and Europe annually[1]
- Up to 40% of women undergoing a mastectomy as primary treatment will experience local recurrence
- Local tumor control is a primary objective in treating these patients

Limited Treatment Options



Complete Response



Combined Phase 1 Data (n = 29)



Phase 2 US DIGNITY Study

Evaluate local-regional breast tumor response. 17 patients enrolled; 12 evaluable for efficacy

- All evaluable patients experienced stabilization of disease; 67% of patients in evaluable population observed local responses - 5 CRs & 3 PRs
- 47% Local Response (ITT)

Celsion

[1] *Agency for Healthcare Research and Quality 2009; Bian et al. 2008; Clemons et al. 2001*

ThermoDox: Euro-DIGNITY Study

ThermoDox + Hyperthermia + Radiation

Primary Objectives

- Evaluate complete and partial response after 3 cycles of ThermoDox + Hyperthermia and Radiation Treatment (Tri-Modal Therapy)
- Evaluate loco-regional breast tumor control in patients undergoing Tri-Modal Therapy

70 patients to be enrolled

Open Label Design

Study Timelines

- Site Activation: Pending
- Expected Recruitment Period: 2017 – 2018



Celsion


GEN-1 IL-12
Immuno-Oncology Program
Celsion
18

IL-12

A Powerful Immune Modulating Agent; Multiple Mechanisms

Mechanisms of Action

1. NK Cell Activation
2. T Cell Activation
3. Anti-angiogenesis
4. T Reg suppression



Celsion

GEN-1

Novel Polymer-Plasmid DNA Nanoparticle

Rationale for Local Therapy with GEN-1 DNA Nanoparticles

- Loco-regional production of potent cytokine IL-12 avoid toxicities and poor pK associated with systemic recombinant IL-12
- Persistent local delivery of IL-12 lasts up to one week and dosing can be repeated
- Ideal for long-term maintenance therapy

100 nm

GEN-1 is an Effective Alternative to rIL-12 Poor pK



Celsion

Ovarian Cancer

Large and Deadly Global Cancer

- **8th most diagnosed cancer among women**
  - 225,000 annual incidence worldwide
  - 22,280 in US and 100,000 in developed countries
  - 14,240 deaths in 2015
- **5th highest mortality among women**
  - 5-year survival rate for all stages is >50%
  - Survival rate reduces dramatically if not localized cancer
  - 15% diagnosed with localized cancer, eligible for potentially curative surgery
- **Local therapies for ovarian cancer**
  - Ovarian cancer is not diagnosed early - spreads to regional/mets requiring combo regimens
  - Most common site of recurrence in abdomen– importance of intra-peritoneal administered therapy
  - GEN-1 administered IP; ideal adjuvant to SoC therapy

Celsion

Sources: Cancer Statistics, American Cancer Society; Globocan; SEER database

GEN-1 for Ovarian Cancer

Local Immunotherapy

Persistent Local Delivery of an Immune Agent with a Single Administration



- GEN-1causes the controlled local production of IL-12 at the cancer site
- IL-12 addresses cancer cells by recruiting the immune system, inducing powerful anti-cancer mechanisms for an immune attack

Celsion

Ovarian Cancer Treatment Path



Ovarian Cancer, US Statistics
22,280 new cases each year
14,240 est. deaths in 2015

Celsion

GEN-1: Preclinical Studies

GEN-1 + Doxil + Avastin

- Doxil + Avastin is 2nd line SoC for platinum-resistant ovarian cancer.
- Adding Avastin Results in a > 98% Reduction in Tumor Burden





HD Doxil = 7.5 mg/kg
LD Doxil = 3.75 mg/kg

N = 8 /group
Animals euthanized 59 days after tumor implant

Celsion

GEN-1 + Doxil Phase 1b Trial

2nd Line

GEN-1 (mg/m^2)	Doxil (mg/m^2)
24	40
36	40
36	50

Clinical Observations

- All doses well tolerated with no DLTs
- Clinical response rate:
  - All doses: **> 50%**
  - Highest dose: **86%**
- Single agent Doxil comparison 4 previous studies:
  - Clinical RR **< 50%**

Translational Data Findings

Significant increase in immunologically active IL-12 levels in peritoneal fluid

- Detectable for at least one week after GEN-1 dosing
- Not detectable or very low in plasma

Significant increase in key downstream mediators of IL-12

- IFN-γ and TNF-α: ~5-fold increase observed in peritoneal fluid above pre-treatment level with the highest increase observed at 77-fold
- Very low to non-detectable levels of IFNγ and TNF-α in plasma

Celsion

GEN-1 Phase I Study

1st Line in Ovarian Cancer

The OVATION Study



Neoadjuvant Study in Newly Diagnosed Ovarian Cancer Patients	To determine safety, dose, and feasibility in target patient population
Primary Endpoint	Optimal Therapeutic Dose
Secondary Endpoints	pCR, PFS, ↑IFNγ, ↑IL-12, ↓VEGF and Tumor-specific T-cell response CD4+,CD8+

Celsion

OVATION Study

Totality of Results in the First Four Patient Cohorts, n=12

- 1st 12 patients dosed, there has been a
  - 100% disease control rate (DCR)
  - 75% objective response rate (ORR)
- Of the 11 surgically treated patients:
  - All patients had successful resections of their tumors
  - One patient demonstrated a complete pathological response (PCR) [1]
  - 55% of patients had a R0 resection (margin-negative resection)
- All show a greater than 90% drop in their CA-125 protein levels [2]
- Ratio of CD8+/FoxP3+ cells was increased in all four evaluable patients demonstrating a potential shift in tumor environment to favoring immune stimulation following NACT + GEN-1 therapy

1 In a 332 patient GOG Study, cPR's were seen in < 6.5% of patients; Strong correlation with improvement in Overall Survival (median OS of 72 mos.) which is a 3 year improvement over patients having a microPR or macroPR (Pvalue = 0.018)

2 50% reduction in CA-125 levels from baseline that is maintained for > 2 weeks is considered a CA-125 Responder

Celsion

GEN-1+Avastin and Doxil Trial Design

2nd Line



Primary Endpoint Phase I Primary Endpoint Phase II	Optimal Safe Dose (Max or MTD) Clinical Objective Tumor Response (RECIST)
Secondary Endpoint	IL-12, IFN-γ, TNF-α, VEGF
Treatment period	28 day cycles continue until GEN-1 or Avastin treatment is no longer tolerated

Celsion


Milestones & Financials
Celsion
29

Milestone Events (2016 - 2018)

	2016				2017				2018			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
ThermoDox												
OPTIMA STUDY		Initiate Enrollment in China √	HEAT Study OS Data (China cohort) √		OPTIMA 50% Complete					OPTIMA Enrollment Complete		1st Interim Efficacy Endpoint
Euro-DIGNITY STUDY						Initiate Enrollment		1st Efficacy Assessment (24 pts)		Enrollment Complete		Final Data Assessment (70 pts)
GEN-1												
OVATION STUDY		Efficacy Data from Cohorts 1 & 2 √	Translational Research Data from Cohorts 1 & 2 √	Efficacy Data from Cohort 3 √	Efficacy Data from Cohort 4 √	Final Efficacy & TR Data from Cohorts 1-4						
Avastin+Doxil Study	TR Data from Phase 1b Ovarian Study √	Pre-Clin Data at AACR √					Submit IND for Ph 1/2 Study	Initiate Enrollment			Efficacy & TR data from Phase 1	Initiate Phase 2 Study
TheraSilence												
Lung Cancer		Pre-Clin Data (Collaboration w/ RNA company √				Potential Co-Development Collaboration						

√ Achieved to-date

Celsion

Financial Overview

Cash & Investments (9/30/16)	$8.7 million
Estimated cash usage per month	~$1.5 million
Market Capitalization	$10 million
Common shares outstanding	31 million
Fully diluted shares outstanding	55 million
Avg Daily Trading Volume	~700,000

Celsion


Corporate Information
Celsion Corporation
997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
P 609-896-9100
F 609-896-2200
www.celsion.com
NASDAQ: CLSN
Celsion